Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is the first clinical study with the BMS-986147 compound in healthy subjects. The purpose of this study is to guide the dose range and dose frequency for future studies with BMS-986147 and will provide guidelines for selection of a potentially effective dose in patients.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| A1: BMS-986147 or Placebo matching BMS-986147 | Placebo Comparator | Single oral dose as specified |
|
| A2: BMS-986147 or Placebo matching BMS-986147 | Placebo Comparator | Single oral dose as specified |
|
| A3: BMS-986147 or Placebo matching BMS-986147 | Placebo Comparator | Single oral dose as specified |
|
| B1: BMS-986147 or Placebo matching BMS-986147 | Active Comparator | Daily oral dose as specified |
|
| B2: BMS-986147 or Placebo matching BMS-986147 | Active Comparator | Daily oral dose as specified |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| BMS-986147 | Drug |
|
| Measure | Description | Time Frame |
|---|---|---|
| Safety and tolerability of single oral dose of BMS-986147 based on incidence of AEs, serious AEs, AEs leading to discontinuation, and death as well as marked abnormalities in clinical laboratory tests, vital sign measurements, and physical examinations | Adverse event (AE) | Up to 30 days post last dose of study drug |
| Safety and tolerability of multiple oral dose of BMS-986147 based on incidence of AEs, serious AEs, AEs leading to discontinuation, and death as well as marked abnormalities in clinical laboratory tests, vital sign measurements, and physical examinations | Up to 30 days post last dose of study drug |
Not provided
Not provided
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bristol-Myers Squibb | Bristol-Myers Squibb | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Wcct Global, Llc | Cypress | California | 90630 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo matching BMS-986147 | Drug |
|